Schizophrenia Market Report 2026

The schizophrenia market size has grown steadily in recent years. It will grow from $6.06 billion in 2025 to $6.35 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increasing prevalence of schizophrenia, expansion of psychiatric hospitals and clinics, availability of first- and second-generation antipsychotics, growing healthcare expenditure in developed markets, improved diagnostic criteria and clinical guidelines.

The schizophrenia market size is expected to see strong growth in the next few years. It will grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to pipeline of novel antipsychotic molecules, growth in long-acting injectable formulations, rising government mental health initiatives, increasing access to treatment in emerging markets, integration of digital monitoring and adherence tools. Major trends in the forecast period include increasing use of long-acting injectable antipsychotics, shift toward second- and third-generation antipsychotic drugs, growing focus on early diagnosis and intervention programs, expansion of community-based and outpatient treatment models, rising adoption of combination therapy and adjunct treatments.

The increasing demand for anxiety treatment is expected to drive the growth of the schizophrenia market in the coming years. Anxiety treatment includes various therapeutic approaches and interventions designed to help individuals manage and reduce excessive and debilitating anxiety symptoms. For people with schizophrenia, addressing comorbid anxiety can help alleviate associated symptoms and may also reduce the severity of psychotic symptoms such as hallucinations and delusions. For example, in May 2024, a report by the American Psychiatric Association, a US-based professional organization of psychologists, noted that 43% of adults reported feeling more anxious in 2024, compared to 37% in 2023 and 32% in 2022, indicating a consistent upward trend in anxiety levels. Therefore, the rising need for anxiety treatment is supporting growth in the schizophrenia market.

Key companies in the schizophrenia market are focusing on technological advancements, such as atypical oral antipsychotics with improved safety and efficacy profiles, to meet growing demand driven by the need for better symptom control, expanded adolescent treatment options, and enhanced tolerability. For instance, in March 2025, Otsuka Pharmaceutical Europe Ltd., a Japan-based healthcare company, in collaboration with H. Lundbeck A/S, a Denmark-based biopharmaceutical company, launched Rxulti (brexpiprazole) for treating schizophrenia in adolescents aged 13 years and older. Rxulti is a once-daily atypical oral antipsychotic that modulates serotonin and dopamine systems as a partial agonist at serotonergic 5-HT1A and dopaminergic D2 receptors, while acting as an antagonist at serotonergic 5-HT2A and noradrenergic α1B/2C receptors. This receptor profile provides balanced control of both positive and negative symptoms, with a favorable safety profile, enhancing patient adherence and outcomes compared to traditional antipsychotics. The European Commission’s approval was based on a rigorous 6-week randomized clinical trial demonstrating significant symptom reduction and good tolerability in adolescent patients.

In March 2023, Royalty Pharma PLC, a US-based purchaser of biopharmaceutical royalties, acquired the royalty rights for KarXT, a schizophrenia treatment, from Karuna Therapeutics Inc. for $500 million. This acquisition provides PureTech with a 3% royalty on Karuna’s annual sales of up to $2 billion, offering additional funds to advance its internal pipeline, including ongoing clinical programs toward potential commercialization. KarXT is an oral investigational therapy designed to treat schizophrenia and other neurological disorders, focusing on M1/M4-preferred muscarinic agonists. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company dedicated to developing treatments for psychiatric disorders and schizophrenia.

Major companies operating in the schizophrenia market are Pfizer Inc, Johnson And Johnson Services Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Otsuka Holdings Co Ltd, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, Sumitomo Dainippon Pharma Co Ltd, Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck AS, Neurocrine Biosciences Inc, Torrent Pharmaceutical Ltd, Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc, Intra Cellular Therapies Inc, Axsome Therapeutics Inc, Karuna Therapeutics Inc, Minerva Neurosciences Inc.

North America was the largest region in the schizophrenia market in 2025. The regions covered in the schizophrenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the schizophrenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the schizophrenia market by increasing costs associated with imported pharmaceuticals, injectable drug delivery devices, and mental health monitoring tools. North America and Europe are most affected due to reliance on international drug manufacturing, while Asia-Pacific faces higher API sourcing costs. These tariffs may raise treatment expenses. However, they are also accelerating domestic drug production and encouraging innovation in cost-efficient mental health therapies.

The schizophrenia market research report is one of a series of new reports that provides schizophrenia market statistics, including schizophrenia industry global market size, regional shares, competitors with a schizophrenia market share, detailed schizophrenia market segments, market trends and opportunities, and any further data you may need to thrive in the schizophrenia industry. This schizophrenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Schizophrenia is a chronic and severe mental disorder that significantly affects an individual’s cognitive functions, emotional expression, behavior, and perception of reality. Symptoms include delusions, hallucinations, disorganized speech, and abnormal movements. Effective management of schizophrenia requires a comprehensive approach, incorporating pharmaceutical treatments, rehabilitation programs, and supportive services.

The main types of schizophrenia include catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, residual schizophrenia, and others. Catatonic schizophrenia is a subtype marked by severe motor disturbances, such as catatonia, immobility, and unusual postures or movements. Management involves antipsychotic medications and supportive therapies to control psychotic symptoms and address catatonic motor behavior. Treatments include first-, second-, and third-generation antipsychotics, psychotherapies, and other therapeutic drugs, administered via oral or injectable routes.

The schizophrenia market consists of revenues earned by entities by providing cognitive behavioral therapy, electroconvulsive therapy, and group counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizophrenia market also includes sales of risperdal, invega, zyprexa, geodon and seroquel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.